BR112018008358A2 - ?composições e métodos para terapia relacionada à microbiota fecal? - Google Patents

?composições e métodos para terapia relacionada à microbiota fecal?

Info

Publication number
BR112018008358A2
BR112018008358A2 BR112018008358-5A BR112018008358A BR112018008358A2 BR 112018008358 A2 BR112018008358 A2 BR 112018008358A2 BR 112018008358 A BR112018008358 A BR 112018008358A BR 112018008358 A2 BR112018008358 A2 BR 112018008358A2
Authority
BR
Brazil
Prior art keywords
methods
compositions
microbiota
fecal microbiota
related therapy
Prior art date
Application number
BR112018008358-5A
Other languages
English (en)
Inventor
Julius Borody Thomas
Original Assignee
Crestovo Holdings Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crestovo Holdings Llc filed Critical Crestovo Holdings Llc
Publication of BR112018008358A2 publication Critical patent/BR112018008358A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

o presente pedido fornece composições, métodos e regimes de dosagem relacionados à microbiota para o tratamento de vários distúrbios relacionados à microbiota com taxas de cura melhoradas substituindo-se ou completando-se ou modificando-se uma microbiota do cólon do sujeito.
BR112018008358-5A 2015-10-26 2016-10-26 ?composições e métodos para terapia relacionada à microbiota fecal? BR112018008358A2 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562246441P 2015-10-26 2015-10-26
US62/246,441 2015-10-26
US201562270159P 2015-12-21 2015-12-21
US62/270,159 2015-12-21
US201662395761P 2016-09-16 2016-09-16
US62/395,761 2016-09-16
PCT/US2016/058938 WO2017075098A1 (en) 2015-10-26 2016-10-26 Compositions and methods for fecal microbiota-related therapy

Publications (1)

Publication Number Publication Date
BR112018008358A2 true BR112018008358A2 (pt) 2019-04-24

Family

ID=57249913

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018008358-5A BR112018008358A2 (pt) 2015-10-26 2016-10-26 ?composições e métodos para terapia relacionada à microbiota fecal?

Country Status (11)

Country Link
US (1) US20170216372A1 (pt)
EP (1) EP3368050A1 (pt)
JP (1) JP2018535254A (pt)
KR (1) KR20180100543A (pt)
CN (1) CN108472315A (pt)
AU (1) AU2016344049A1 (pt)
BR (1) BR112018008358A2 (pt)
CA (1) CA3003138A1 (pt)
MX (1) MX2018005107A (pt)
RU (1) RU2018118651A (pt)
WO (1) WO2017075098A1 (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
CN103124559B (zh) 2010-08-04 2017-03-29 托马斯·朱利叶斯·波洛迪 用于粪便菌群植入的组合物及其制备和使用方法以及递送该组合物的装置
CA3119918A1 (en) 2011-03-09 2012-09-13 Regents Of The University Of Minnesota Compositions and methods for transplantation of colon microbiota
EP3212001A4 (en) 2014-10-31 2018-04-25 Whole Biome Inc. Methods and compositions relating to microbial treatment and diagnosis of disorders
FR3035328B1 (fr) 2015-04-24 2019-08-23 Maat Pharma Procede de preparation d'un echantillon de microbiote fecal
FR3035317B1 (fr) 2015-04-24 2019-06-14 Maat Pharma Dispositif de prelevement de micro-organismes, kit de prelevement comprenant un tel dispositif et procede de prelevement mettant en œuvre un tel dispositif
CA2986485A1 (en) 2015-05-22 2016-12-01 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
FR3045383B1 (fr) 2015-12-18 2019-06-14 Maat Pharma Procede de lyophilisation d'un echantillon de microbiote fecal
US9999641B2 (en) 2016-06-14 2018-06-19 Vedanta Biosciences, Inc. Treatment of clostridium difficile infection
US20170360848A1 (en) 2016-06-15 2017-12-21 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
US20180036352A1 (en) 2016-08-03 2018-02-08 Crestovo Holdings Llc Methods for treating ulcerative colitis
US11026978B2 (en) 2016-10-11 2021-06-08 Finch Therapeutics Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
US10092601B2 (en) 2016-10-11 2018-10-09 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
WO2018071536A1 (en) * 2016-10-11 2018-04-19 Crestovo Holdings Llc Compositions and methods for treating primary sclerosing cholangitis and related disorders
CA3058943C (en) 2017-04-03 2023-10-17 Gusto Global, Llc Rational design of microbial-based biotherapeutics
US11433102B2 (en) 2017-04-05 2022-09-06 Finch Therapeutics Holdings Llc Compositions and methods for treating Parkinson's disease (PD) and related disorders
US11040073B2 (en) 2017-04-05 2021-06-22 Finch Therapeutics Holdings Llc Compositions and methods for treating diverticulitis and related disorders
WO2018218159A1 (en) 2017-05-26 2018-11-29 Crestovo Holdings Llc Lyophilized compositions comprising fecal microbe-based therapeutic agents and methods for making and using same
EP3664823B1 (en) 2017-08-07 2024-06-05 Finch Therapeutics Holdings LLC Composition for use in preventing or treating an enterococcal blood stream infection
CN111372596A (zh) 2017-08-30 2020-07-03 潘德勒姆治疗公司 用于治疗微生物组相关病症的方法和组合物
CN108796100B (zh) * 2018-06-21 2020-09-29 中国科学院微生物研究所 基于惰性真杆菌预测艾滋病人haart治疗效果的引物
US11166990B2 (en) 2018-07-13 2021-11-09 Finch Therapeutics Holdings Llc Methods and compositions for treating ulcerative colitis
CA3114423A1 (en) 2018-09-27 2020-04-02 Finch Therapeutics Holdings Llc Compositions and methods for treating epilepsy and related disorders
US20220211771A1 (en) * 2019-04-19 2022-07-07 Pitt Hopkins Research Foundation Microbiota transfer therapy for pitt hopkins syndrome
US20240131082A1 (en) * 2019-10-18 2024-04-25 Finch Therapeutics Holdings Llc Compositions and Methods for Delivering a Bacterial Metabolite to a Subject
TW202122585A (zh) * 2019-12-11 2021-06-16 香港商微生物菌群創新中心有限公司 治療細菌感染的方法
CN111249314B (zh) * 2020-03-03 2022-03-29 深圳未知君生物科技有限公司 人体共生菌群在提高肿瘤免疫治疗应答中的作用
CN111505288B (zh) * 2020-05-15 2022-03-01 重庆医科大学 一种新的抑郁症生物标志物及其应用
WO2022051610A1 (en) * 2020-09-04 2022-03-10 Ferring B.V. Microbiota restoration therapy (mrt) compositions and methods of manufacture
CN112048565B (zh) * 2020-09-15 2023-04-28 石家庄市人民医院(石家庄市第一医院、石家庄市肿瘤医院、河北省重症肌无力医院、石家庄市心血管病医院) 源于肠道的诊断重症肌无力的菌群及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4394377A (en) 1981-07-31 1983-07-19 Syntex (U.S.A.) Inc. Ruminant animal performance by co-administering choline and propionate enchancers
CN103124559B (zh) 2010-08-04 2017-03-29 托马斯·朱利叶斯·波洛迪 用于粪便菌群植入的组合物及其制备和使用方法以及递送该组合物的装置
CA3119918A1 (en) 2011-03-09 2012-09-13 Regents Of The University Of Minnesota Compositions and methods for transplantation of colon microbiota
WO2014152484A1 (en) 2013-03-14 2014-09-25 Regents Of The University Of Minnesota Freeze dried fecal microbiota for use in fecal microbial transplantation
EP3659598A1 (en) * 2012-06-04 2020-06-03 Gaurav Agrawal Compositions and methods for treating crohn's disease and related conditions and infections
US8906668B2 (en) * 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
US9782445B2 (en) * 2013-06-05 2017-10-10 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9511099B2 (en) * 2013-06-05 2016-12-06 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture

Also Published As

Publication number Publication date
CN108472315A (zh) 2018-08-31
KR20180100543A (ko) 2018-09-11
MX2018005107A (es) 2018-08-09
CA3003138A1 (en) 2017-05-04
WO2017075098A1 (en) 2017-05-04
EP3368050A1 (en) 2018-09-05
RU2018118651A (ru) 2019-12-04
US20170216372A1 (en) 2017-08-03
AU2016344049A1 (en) 2018-05-10
JP2018535254A (ja) 2018-11-29

Similar Documents

Publication Publication Date Title
BR112018008358A2 (pt) ?composições e métodos para terapia relacionada à microbiota fecal?
CO2019013707A2 (es) Polinucleótidos de aadc para el tratamiento de la enfermedad de parkinson
CY1121170T1 (el) Νεες ενωσεις ως ρυθμιστες πρωτεϊνικων κινασων
BR112018004620A2 (pt) moduladores da expressão de kras
BR112018003984A2 (pt) anticorpos
BR112017025045A2 (pt) plx-8394 ou plx-7904 para uso no tratamento de doenças relacionadas a braf-v600
BR112017005693A2 (pt) método para tratar e/ou prevenir uma doença hepática, e, composição farmacêutica.
MX2019003938A (es) Compuestos espirociclicos.
MX2017016134A (es) Aril dihidro-2h-benzo[b][1,4]oxazina sulfonamida y compuestos relacionados para uso como agonistas de rory y el tratamiento de enfermedad.
BR112019001615A2 (pt) métodos e composições para tratar mielofibrose
NZ737399A (en) Ccr2 modulators
DOP2016000237A (es) Terapia genica para la retinitis pigmentaria
BR112017023579A2 (pt) combinação de um anticorpo cd30xcd16 com um antagonista de pd-1 para terapia
EA201590654A1 (ru) Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона
BR112019003579A2 (pt) Composições de ribosídeo de nicotinamida e pterostilbeno e métodos para o tratamento dedistúrbios neurodegenerativos
PH12019501018A1 (en) Pharmaceutical composition, methods for treating and uses thereof
BR112019003577A2 (pt) métodos de tratamento da semente e produtos resultantes
BR112015026247A2 (pt) métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
BR112014019399A2 (pt) métodos de tratamento da fibrose
BR112017014361A2 (pt) métodos para aperfeiçoamento de terapia celular
BR112017022653A2 (pt) ?métodos para o tratamento ou para a prevenção de uma doença, da artrite reumatoide, da prostatite e da bph?
BR112017021194A2 (pt) compostos espirocíclicos
CY1125113T1 (el) Συνθεσεις και μεθοδοι για χρηση στην αγωγη της ομοκυστινουριας
BR112017021583A2 (pt) métodos para o tratamento de transtornos inflamatórios

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]